APSR2026-772

Yes
Late-Breaking
Submitted
Poster Presentation
 
AP11-018
P60
 
Format: PPTX Only
https://storage.unitedwebnetwork.com/files/1285/1221215-46904-APSR26_Poster UAE_435139.pdf
Format: PDF Only
09. Asthma
4

No more than 15 authors can be listed.
Please ensure the authors are listed in the right order.
If there are multiple affiliations, please use the "+" button next to "Select Country/Region" to add additional affiliation fields.

Gopal Chawla - NMC Royal DIP Specialist Pulmonologist, Head of Pulmonology Dept. Dubai United Arab Emirates
Aniruddha Mukhopadhyay - Cipla Ltd Global Medical Affairs Mumbai India
Jaideep Gogtay - Cipla Ltd Global Medical Affairs Mumbai India
Vaibhav Gaur * Cipla Ltd Global Medical Affairs Mumbai India
 
 
 
 
 
 
 
 
 
 
 
Presenting Author Details
Vaibhav
Gaur
vaibhav2india@gmail.com
+919830061506
51-60
United Arab Emirates
Original Research
Perceptions of the Management of Asthma in United Arab Emirates: A specialty-wise Analysis
Maximum 25 words
Abstract Content
Asthma presents a huge burden in United Arab Emirates. Real world asthma care may vary across specialties. We assessed perceptions among specialties to identify convergence and divergence in asthma management.
This was a cross sectional survey of 93 participants from three emirates (Dubai, Abu Dhabi, Sharjah): physicians(20%), pulmonologists(25%), general practitioners(GPs,28%), pediatricians(27%).
The proportion of asthma patients among their respective respiratory cases was high for pulmonologists(41%) and pediatricians(41%), and low for GPs(21%) and physicians(16.5%). Proportion of patients with mild asthma (GINA 1–2) were higher among pediatricians(63%), physicians(55%) and GPs(55%), versus pulmonologists(35.5%); whereas GINA 3–5 was more with pulmonologists. Preference for low dose ICS/formoterol as reliever for mild asthma was highest among pulmonologist(78%), followed by physicians(57%) and GPs(51%); whereas pediatricians showed lowest preference(32%), with greater reliance on SABA(37%). Formoterol/budesonide was the most preferred reliever for mild asthma. For choosing controller for mild asthma, all specialties reported as-needed low dose ICS(28-48%) and low-dose ICS/formoterol(26-39%) were preferred therapies. For asthma Steps 3-5, ICS/formoterol based regimens were preferred by pulmonologists(75%), followed by GPs(69.5%), physicians(63%), and pediatricians(58.5%). For reliever in steps 3–5, as needed low dose ICS/formoterol was the preferred(41-72%) by all specialties, highest preference among pulmonologists(72%). Proportion of patients that effectively use budesonide/formoterol as MART were 78.5%, 67%, 69% and 57% among pulmonologists, pediatricians, GPs, and physicians, respectively. >95% across specialties agreed that choosing right device improves adherence. pMDI with/without spacer was preferred most. 86% pediatricians reported regular follow ups ensure patient adherence. Inhibition towards inhalation therapy was observed by pediatricians(36%), pulmonologists(33%), GPs(29%) and physicians(25%), where >50% were GINA 1–2 patients.
Practice patterns vary by specialty; pulmonologists show highest adoption of ICS/formoterol strategies across GINA steps, while pediatricians’ practice retains higher SABA use. The survey highlighted opportunities for training physicians, GPs and pediatricians to align their treatment strategies with GINA 2026 strategies.
 
 
 
 
 
No
No
 
JPG or JPEG or PNG format ONLY
Asthma, MART, United Arab Emirates
maximum 3 keywords and no abbreviations, separated by commas
 
344